Bufei Jianpi Granule for Delaying Pulmonary Function Decline in Early-Stage COPD

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

Bufei Jianpi Granule for Delaying Pulmonary Function Decline in Early-Stage COPD: A Randomized, Double-blind, Placebo Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03976700
• Other study ID #: TCM for Early-Stage COPD
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: June 2019
• Est. completion date: December 2021

Study information

• Verified date: May 2019
• Source: Henan University of Traditional Chinese Medicine
• Contact: Suyun Li, Professor
• Phone: 86-371-66248624
• Email: lisuyun2000[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to establish the treatment scheme of Bufei Jianpi granule for early-stage (GOLD stage 1 or 2) chronic obstructive pulmonary disease (COPD), delaying pulmonary function decline and forming high quality evidence.

Description:

COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. More than 70% of patients with COPD are in GOLD stage 1 (mild) or 2 (moderate), with very mild or no apparent respiratory symptoms such as dyspnea. The Tiotropium in Early Chronic Obstructive Pulmonary Disease Patients in China (Tie-COPD) trial was designed to investigate the effect of tiotropium on the FEV1 in COPD patients with GOLD stage 1 or 2. The investigator's previous studies also suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 1 or 2 COPD.

This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Jianpi granule for delaying pulmonary function decline in early-stage (GOLD stage 1 or 2) COPD subjects. After a 14-day run-in period, 612 subjects will be randomly assigned to treatment group or control group for 104-week treatment. The primary outcomes include pulmonary function and frequency of acute exacerbation. The secondary outcomes include clinical symptoms, dyspnea, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 612
• Est. completion date: December 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• A confirmed diagnosis of early-stage (GOLD stage 1 or 2) COPD.

• Syndrome differentiation meets criteria of Qi deficiency of the lung syndrome, Qi deficiency of the lung and spleen syndrome or Qi deficiency of the lung and kidney syndrome.

• Age ranges from 40 years to 80 years.

• With informed consent signed.

Exclusion Criteria:

• Pregnant and lactating women.

• Patients with severe cardiovascular and cerebrovascular diseases.

• Patients with severe liver and kidney diseases.

• Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism or other severe respiratory diseases.

• Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.

• Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.

• Patients with severe cognitive and psychiatric disorders.

• Patients with diabetes.

• People who are allergic to the treatment drugs.

• Patients who have participated in other clinical studies in the past 4 weeks.

• Patients who have experienced one or more acute exacerbation in the past 4 weeks.

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Bufei Jianpi granule
Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
• Placebo Bufei Jianpi granule
Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Henan University of Traditional Chinese Medicine	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Henan University of Traditional Chinese Medicine	Jiangsu Province Hospital of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FEV1	Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function.	Change from baseline FEV1 at week 26, 52, 78 and 104.
Primary	Frequency of acute exacerbation	Frequency of acute exacerbation will be recorded.	Up to week 104.
Secondary	Clinical symptom assessment questionnaire	Clinical symptom assessment questionnaire of COPD will be used to assess symptom.	Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	mMRC	The modified Medical Research Council dyspnoea scale (mMRC) will be used to assess severity of dyspnea.	Change from baseline mMRC scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	6MWD	Six-minute walk distance (6MWD) will be conducted to assess exercise capacity.	Change from baseline 6MWD at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	CAT	The COPD assessment test (CAT) is a self-administered questionnaire that measures health-related quality of life.	Change from baseline CAT scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	SF-36	The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life.	Change from baseline SF-36 scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	mCOPD-PRO	The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status.	Change from baseline mCOPD-PRO scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	EQ-5D	EuroQol 5D (EQ-5D) will be used to assess quality of life.	Change from baseline EQ-5D scores at week 13, 26, 39, 52, 65, 78, 91 and 104.
Secondary	mESQ-COPD	The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction.	Change from baseline mESQ-COPD scores at week 13, 26, 39, 52, 65, 78, 91 and 104.